Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

scientific article published on 27 May 2010

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/LEU.2010.99
P698PubMed publication ID20508609
P5875ResearchGate publication ID44636151

P50authorDaniela PietraQ42033215
Francesco PassamontiQ42389421
Robert KralovicsQ29887665
Ashot HarutyunyanQ42033212
P2093author name stringM Cazzola
T Berg
R Jäger
B Gisslinger
H Gisslinger
E Rumi
T Klampfl
D Olcaydu
P2860cites workTaxing sugar-sweetened beveragesQ43180928
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsQ44008600
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disordersQ46913469
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasmsQ47960630
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.Q50721189
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.Q51761197
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.Q51768323
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.Q51806902
Ikaros is critical for B cell differentiation and function.Q52123185
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.Q54511975
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosQ57734316
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphomaQ71806450
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesQ80607021
Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasmsQ95779600
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisQ24609999
Recurring mutations found by sequencing an acute myeloid leukemia genomeQ24634204
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportQ27851487
Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitmentQ28202932
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraQ28241887
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Q28243103
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemiaQ28253771
Multiple hematopoietic defects and delayed globin switching in Ikaros null miceQ28510404
The Ikaros gene is required for the development of all lymphoid lineagesQ28594316
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisQ29614337
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screenQ29615061
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivoQ29616612
A gain-of-function mutation of JAK2 in myeloproliferative disordersQ29618851
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersQ29618853
Mutation in TET2 in myeloid cancersQ29619292
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemiasQ34162729
Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutationQ34412659
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaQ34770384
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation modelQ35849213
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemiaQ36185370
The myeloproliferative disordersQ36675917
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemiaQ37172988
JAK mutations in high-risk childhood acute lymphoblastic leukemiaQ37224111
Genetic complexity of myeloproliferative neoplasms.Q37255024
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevanceQ38440701
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto AcuteQ39826912
Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levelsQ39984463
P433issue7
P304page(s)1290-1298
P577publication date2010-05-27
P1433published inLeukemiaQ6534498
P1476titleDeletions of the transcription factor Ikaros in myeloproliferative neoplasms.
P478volume24

Reverse relations

cites work (P2860)
Q36858928A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints
Q43010395A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells.
Q42583748Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.
Q36147014Alternative Splice Variants Modulates Dominant-Negative Function of Helios in T-Cell Leukemia
Q34233335An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations
Q34166859Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management
Q33558154Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase
Q92915669Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Q38050656B-lineage transcription factors and cooperating gene lesions required for leukemia development
Q38014534BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques
Q26777265Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
Q39399799CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.
Q36964853CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation
Q43405916Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Q55030822Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.
Q34302770Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms
Q39144353Direct protein interactions are responsible for Ikaros-GATA and Ikaros-Cdk9 cooperativeness in hematopoietic cells
Q43112746Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression
Q33413428Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
Q38999178Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts
Q51250068Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Q42183250EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations
Q36001930Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
Q38329285Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Q35995222Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Q38066786Genetic and epigenetic alterations of myeloproliferative disorders
Q38159973Genetic basis of MPN: Beyond JAK2-V617F.
Q26823651Genetics of myeloproliferative neoplasms
Q41932257Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach
Q35835653IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
Q42415934IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications
Q34348505Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing
Q38371003Ikaros and leukaemia
Q36730409Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling
Q53240971Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation.
Q42057738Ikaros: master of hematopoiesis, agent of leukemia
Q57465846Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
Q38127417Inherited predisposition to myeloproliferative neoplasms
Q34786517Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma
Q34150008JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
Q36612537JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.
Q38044736JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Q37833893Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Q38050756Molecular biology of Philadelphia-negative myeloproliferative neoplasms
Q54574818Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
Q50072000Mutations in myeloproliferative neoplasms - their significance and clinical use.
Q40298579Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Q37877727Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Q34629928Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies
Q37869152New JAK2 inhibitors for myeloproliferative neoplasms
Q36909019Normal and malignant megakaryopoiesis
Q49978793Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
Q38926804Prognosis of Primary Myelofibrosis in the Genomic Era
Q40727272Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients
Q36709009Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia
Q35103926Regulator of myeloid differentiation and function: The secret life of Ikaros
Q83141302Role of TET2 mutations in myeloproliferative neoplasms
Q38100790Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians
Q33393587Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
Q38683077The evolution and clinical relevance of prognostic classification systems in myelofibrosis
Q53703572The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.
Q33850043The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma
Q36594686Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia
Q37968531Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Q42870230Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology